Effects of steroidal saponin RCE-4 from Reineckia Carnea (Andr.) Kunth on Ras/Erk and p16/cyclinD1/ CDK4 signaling pathways in the human cervix cancer Caski cells

doi:10.12092/j.issn.1009-2501.2018.03.002

Abstract

Abstract:

AIM: To investigate the effects of steroidal saponin RCE-4 from Reineckia Carnea (Andr.) Kunth on Ras/Erk and p16/cyclinD1/CDK4 signaling pathways in the human cervix cancer Caski cells, and to explore its possible mechanism. METHODS: The Caski cell line was cultured in vitro, the cell viability and the distribution of cell cycle was detected by MTT and flow cytometry, respectively; the quantitative real-time PCR was used to evaluate the mRNA expressions of p16, cell cycle-related cyclinD1 and CDK4；Western blot was used to determine the total protein and phosphorylated protein of Ras/Erk signaling pathway. RESULTS:RCE-4 could significantly inhibit the growth of Caski cells compared with the control group, the IC50 was 12.33 μmol/L in the 24 h, and it increased the percentage of G0/G1 phase cells, decreased the percentage of S phase cells, inhibited the proteins levels of Ras, p-Raf, p-Mek1/2 and p-Erk1/2, decreased the p-Raf:Raf,p-Mek1/2:Mek1/2 and p-Erk1/2:Erk1/2 ratios, up-regulated the mRNA expression of p16, down-regulated the expressions level of cyclinD1 and CDK4. CONCLUSION: RCE-4 could significantly inhibit the proliferation of Caski cells and induce the cells to block in G0/G1 phase, and the mechanism is related to inhibiting the Ras/Erk and p16/cyclinD1/CDK4 signaling pathways.

Key words: RCE-4, cell cycle, Caski cells, Ras/Erk signaling pathway, p16/cyclinD1/CDK4 signaling pathway

CLC Number:

R965.2

YAN Weihong, ZOU Kun, HE Haibo, ZHANG Yongfeng, LI Xiaomei, LI Xiaoqin, YANG Xiaojiao, WANG Junzhi, DENG Zhangshuang. Effects of steroidal saponin RCE-4 from Reineckia Carnea (Andr.) Kunth on Ras/Erk and p16/cyclinD1/ CDK4 signaling pathways in the human cervix cancer Caski cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 247-254.

References

［1］周琴, 杨小姣, 石孟琼, 等. 南赤瓟醇提物通过PI3K/Akt/mTOR信号通路促进人宫颈癌Caski细胞凋亡［J］.中国临床药理学与治疗学, 2016, 21 (1):42-49.
［2］Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives［J］. Cancer Treat Rev, 2017, 59:109-116.
［3］Lin J, Chen LT, Qiu XM, et al. Traditional Chinese medicine for human papillomavirus (HPV) infections: a systematic review［J］. Biosci Trends, 2017, 11(3): 267-273.
［4］卢小丰, 尉小琴, 刘呈雄, 等. RCE-４结构改造及其抗肿瘤活性的研究［J］. 三峡大学学报(自然科学版), 2015, 37(3): 104-107.
［5］Bai CH, He HB, Cheng F, et al. A steroidal saponin RCE-4 inhibits lipopolysaccharide- stimulated inflammatory responses via blocking PI3K/Akt-mediated NF-κB activation in RAW264.7 cells［J］. Applied Mechanics and Materials, 2014, 568-570: 1901-1906.
［6］杨小姣, 邹坤, 尉小琴, 等. 吉祥草中甾体皂苷RCE-4激活p53-ROS通路诱导人肝癌 HepG2细胞凋亡的机制研究［J］. 中药药理与临床, 2016, 32(2): 62-67.
［7］Bai CH, Yang XJ, Zou K, et al. Antiproliferative effect of RCE-4 from Reineckia Carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation［J］. Naunyn Schmiedebergs Arch Pharmacol, 2016, 389(6):573-584.
［8］杨小姣, 白彩虹, 邹坤, 等. 吉祥草中甾体皂苷RCE-4对宫颈癌裸鼠移植瘤的抑制作用［J］. 第三军医大学学报, 2016, 38(5): 476-482.
［9］Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis ［J］. Cancer, 2017, 123(13): 2404-2412.
［10］王轶英, 王悦, 乔友林, 等. 中国宫颈癌筛查未来之路—细胞学初筛的弃或守［J］.中国实用妇科与产科杂志, 2017, 33(3): 324-326.
［11］李丹温, 玉芳, 刘怡安. 康莱特注射液联合放化疗治疗中晚期宫颈癌50例［J］. 长春中医药大学学报, 2015, 31(1): 151-153.
［12］Mallmann P, Mallmann C. Neoadjuvant and adjuvant chemotherapy of cervical cancer［J］. Oncol Res Treat, 2016, 39(9): 522-524.
［13］Lin WF, Lu JY, Cheng BB, et al. Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment［J］. J Integr Med, 2017, 15(4): 282-287.
［14］中华本草编委会. 中华本草(第8册22卷)［M］. 上海: 上海科学技术出版社，1999：178-180.
［15］Mahapatra DK, Asati V, Bharti SK. MEK inhibitors in oncology: a patent review (2015-Present)［J］. Expert Opin Ther Pat, 2017, 27(8): 887-906.
［16］Richman J, Martin-Liberal J, Diem S, et al. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma［J］. Expert Opin Pharmacother, 2015, 16(9):1285-1297.
［17］Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update［J］. Arch Toxicol, 2015, 89(6): 867-882.
［18］Yang SF, Liu GH. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma［J］. Oncol Lett, 2017, 13(3): 1041-1047.
［19］Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives［J］. Eur J Med Chem, 2016, 109: 314-341.
［20］Matson JP, Cook JG. Cell cycle proliferation decisions: the impact of single cell analyses［J］. FEBS J, 2017, 284(3): 362-375.
［21］Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma［J］. Curr Opin Oncol, 2015, 27(2): 141-150.
［22］Augereau P, Patsouris A, Bourbouloux E, et al. Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy［J］. Ther Adv Med Oncol, 2017, 9(5): 335-346.

[1]	YE Kaili, ZHENG Wen, YE Qifa, YANG Lan . Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
[2]	QIN Boyu, WANG Gang, QI Xiaoguang, WANG Yajie, SUN Qiong, SUN Shengjie. Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1027-1030.
[3]	YAN Huifang, XU Hao, PENG Xiwei, ZHU Jiahuan, DENG Changqing. Effects of Astragalus-Angelica combination on VSMC proliferation of vascular intimal hyperplasia in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 361-369.
[4]	ZHANG Xue-fei, ZHU Xuan-xuan, LIU Shen-lin, WANG Qiong, YAN Shi-hai, WANG Hai-dan, ZHANG Di, FU Rui. Effect of Weiliuan of different prescriptions on proliferation and cell cycle of human gastric carcinoma cell line SGC-7901 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 31-37.
[5]	SUN Shi-hua, JIANG Rong-hua, ZHU Hai-yan, JIANG Jian-jun. Anticancer effects of hyperoside on human gastric cancer cells and its mechanisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 979-983.
[6]	HUANG Hou-bao, XIA Dong-dong, SHEN Qun-shan, CHEN Qing-shui, WANG Xiao, QIU Teng. Effect of bufalin on the proliferation and apoptosis of human bladder cancer T24 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 733-737.
[7]	GUO Chen-xu, QIAN Jun. Effect of poria on the proliferation of the side population of gastric cancer cell line SGC-7901 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1222-1226.
[8]	QIAN Su-bo, CHEN Mu, SHEN Hai-bo, QI Jun. Effects of shRNA targeting IGF2 gene on the growth and cell cycle of human bladder cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1233-1237.
[9]	LU Xin-hua, HUANG Huang, TANG Bing, DENG Hua-fei, WANG Gui-xia, ZUO Ke-qiang, LI Jian, HE Jun-shan. Effects of portulaca total flavone on proliferation of vascular smoothmuscle stimulated by PDGF-BB [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 156-160.
[10]	MAO Jie, SHENG Li-li, XU Shan-shui, WANG Xuan-zhi. Influence on cell proliferation and invasiveness of human astrocytic glioma cell line SHG-44 by baicalein [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 750-754.
[11]	DENG Shui-xiu, ZENG Si-yu, REN Jun-fang, ZHENG Yuan-bin, LIAO Duan-fang, QIN Xu-ping. Effect of CGRP on the CDK2 and Cyclin E of rat vascular smooth muscle cell [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 249-253.
[12]	SUN Sheng-jie, WU Zhi-yong, JIAO Shun-chang. Experimental study of enhanced cytotoxicity of Gemcitabine to human pulmonary carcinoma PLA-801D cells by hyperthermia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1210-1215.
[13]	WANG Wei, WANG Yu, WANG Ruo-ning, XU Su-ying, DING Yang, ZHOU Jian-ping. Study on effects of novel cationic polymer nonviral vector-mediated wild-type p53 gene transfection in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1227-1233.
[14]	XU Xiao-jing, ZHOU Hong-hao, LIU Zhao-qian. Recent research progress of eIF3 in biological function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 219-224.
[15]	YE Hong-zhi, LI Xi-hai, LIANG Wen-na, ZHENG Chun-song, CHEN Wen-lie, LIU Xianxiang. Effects of Tougu Xiaotong Granula(TXG)-containing serum on proliferation of rabbit chondrocytes in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 624-628.